DK1409497T3 - Fremgangsmåde til fremstilling af LNA-phosphoramiditer - Google Patents

Fremgangsmåde til fremstilling af LNA-phosphoramiditer

Info

Publication number
DK1409497T3
DK1409497T3 DK02764561T DK02764561T DK1409497T3 DK 1409497 T3 DK1409497 T3 DK 1409497T3 DK 02764561 T DK02764561 T DK 02764561T DK 02764561 T DK02764561 T DK 02764561T DK 1409497 T3 DK1409497 T3 DK 1409497T3
Authority
DK
Denmark
Prior art keywords
preparation
lna phosphoramidites
cyanoethyl
phosphoramidites
lna
Prior art date
Application number
DK02764561T
Other languages
Danish (da)
English (en)
Inventor
Daniel Sejer Pedersen
Troels Koch
Christoph Rosenbohm
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1409497T3 publication Critical patent/DK1409497T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Luminescent Compositions (AREA)
  • Saccharide Compounds (AREA)
DK02764561T 2001-07-12 2002-07-12 Fremgangsmåde til fremstilling af LNA-phosphoramiditer DK1409497T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101095 2001-07-12
PCT/DK2002/000488 WO2003006475A2 (en) 2001-07-12 2002-07-12 Method for preparation of lna phosphoramidites

Publications (1)

Publication Number Publication Date
DK1409497T3 true DK1409497T3 (da) 2005-05-30

Family

ID=8160624

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02764561T DK1409497T3 (da) 2001-07-12 2002-07-12 Fremgangsmåde til fremstilling af LNA-phosphoramiditer

Country Status (7)

Country Link
EP (1) EP1409497B1 (https=)
JP (1) JP4402454B2 (https=)
AT (1) ATE287413T1 (https=)
AU (1) AU2002328792A1 (https=)
DE (1) DE60202681T2 (https=)
DK (1) DK1409497T3 (https=)
WO (1) WO2003006475A2 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
DK1592793T3 (da) 2003-02-10 2009-10-26 Santaris Pharma As Oligomeriske forbindelser for modulation af Survivin ekspression
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
ATE443765T1 (de) 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
WO2005061710A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
WO2006050732A2 (en) 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
MX2007005558A (es) 2004-11-09 2008-01-31 Santaris Pharma As Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
CA2689602A1 (en) 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US9211537B2 (en) 2007-11-07 2015-12-15 The University Of British Columbia Microfluidic device and method of using same
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
EP3099798B1 (en) 2014-01-29 2018-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
US10533172B2 (en) 2014-09-18 2020-01-14 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
JP6835826B2 (ja) * 2015-08-24 2021-02-24 ロシュ イノベーション センター コペンハーゲン エーエス Ｌｎａ−ｇプロセス
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
EP3494219A1 (en) 2016-08-03 2019-06-12 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
WO2019076919A1 (en) 2017-10-17 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) COMBINED TREATMENT OF CYSTIC FIBROSIS
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
EP3997225A1 (en) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of epilepsy
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
IL292286A (en) * 2019-10-18 2022-06-01 Daiichi Sankyo Co Ltd Production method for bicyclic phosphoramidite
KR20220098217A (ko) 2019-11-13 2022-07-11 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
KR20230050336A (ko) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 뇌전증을 치료하기 위한 방법과 조성물
CN116472276A (zh) * 2020-12-11 2023-07-21 雅玛山酱油株式会社 胞嘧啶型交联型核苷亚磷酰胺晶体及其制造方法
CN117280030A (zh) 2021-02-12 2023-12-22 梅兰德制药公司 用于治疗缺氧和缺血相关病症的药剂、组合物和方法
WO2022200633A1 (en) 2021-03-26 2022-09-29 Neumirna Therapeutics Aps Microrna-27b inhibitors
AU2022245292A1 (en) 2021-03-26 2023-10-12 Neumirna Therapeutics Aps Microrna-134 inhibitors
WO2022254021A1 (en) 2021-06-04 2022-12-08 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
CN118202050A (zh) 2021-08-17 2024-06-14 韩国科学技术院 靶向cav3.1基因的反义寡核苷酸及其用途
EP4388096A1 (en) 2021-08-19 2024-06-26 Neumirna Therapeutics ApS Antisense oligonucleotides targeting adenosine kinase
JP7772362B2 (ja) * 2021-12-21 2025-11-18 シンクレスト株式会社 人工核酸モノマーの製造方法
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
EP4646478A1 (en) 2023-01-06 2025-11-12 Institut National de la Santé et de la Recherche Médicale Intravenous administration of antisense oligonucleotides for the treatment of pain
EP4450626A1 (en) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Fnip2 inhibitors for treating ataxia telangiectasia
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
EP4512899A1 (en) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4 aso compositions for treatment of atherosclerosis in humans
CN117233282B (zh) * 2023-09-14 2024-12-20 上海奥锐特生物科技有限公司 2-氰乙基-n,n,n’,n’-四异丙基亚磷酰二胺的检测方法
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2026061986A1 (en) 2024-09-17 2026-03-26 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026068729A1 (en) 2024-09-26 2026-04-02 Neumirna Therapeutics Aps Antimir-27b for treatment of parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4800197A (en) * 1996-10-15 1998-05-11 Nexstar Pharmaceuticals, Inc. Improved coupling activators for oligonucleotide synthesis

Also Published As

Publication number Publication date
WO2003006475A3 (en) 2004-02-26
AU2002328792A1 (en) 2003-01-29
JP4402454B2 (ja) 2010-01-20
WO2003006475A2 (en) 2003-01-23
DE60202681D1 (de) 2005-02-24
EP1409497A2 (en) 2004-04-21
JP2004536125A (ja) 2004-12-02
DE60202681T2 (de) 2006-01-12
ATE287413T1 (de) 2005-02-15
EP1409497B1 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
DK1409497T3 (da) Fremgangsmåde til fremstilling af LNA-phosphoramiditer
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
DE50204719D1 (de) Verfahren zum bereitstellen von leistungsmerkmalen für alternativ-verbindungen von primär-verbindungen
ATE506372T1 (de) Verfahren zur herstellung von nukleosidderivate
MXPA04002067A (es) Nuevas dihidropteridinonas, procedimientos para su preparacion y su uso como medicamento.
DK0824598T3 (da) Fremgangsmåde til specifik kobling af kappen på ende-5' af et mRNA fragment og fremstilling af komplet mRNA og cDNA
EA200001102A1 (ru) Способ синтеза ингибиторов сох-2 (циклооксигеназы-2)
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DE69813792D1 (de) Zwischenprodukte und verfahren zu ihrer herstellung
BRPI0412558A (pt) processo para a preparação de derivados de tetrazol de azidas de organoboro e organoalumìnio
DK1325022T3 (da) Fremgangsmåde til fremstilling af 21-hydroxy-6,19-oxidoprogesteron (21OH-6OP)
ATE270275T1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5- halogen-pyridinen, verwendbar als cox-2 inhibitoren
ES2171737T3 (es) Conjugados de metaloceno-fosforamidita, procedimiento para producirlos y utilizacion de los mismos.
EA200401350A1 (ru) Способ получения комбретастатинов
DE60219950D1 (de) Verfahren zur überwachung/bekämpfung von thysanoptera
DK1066276T3 (da) Fremgangsmåde til syntese af HIV protease inhibitor
ES2185196T3 (es) Un procedimiento para la preparacion de tetraazamacrociclos.
DK0975601T3 (da) Fremgangsmåde til fremstilling af butylthio-isoquinolin og mellemprodukter derfor
DK0970052T3 (da) Fremgangsmåde til fremstilling af 5-aminomethyl-2-chlorpyridiner
DK1280752T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-chlorphenoler
PT1250335E (pt) Processo e intermediarios para a preparacao de imidazopiridinas
NO20031137D0 (no) Fremgangsmåte for fremstilling av kirale forbindelser
NO20030605D0 (no) Fremgangsmåte for fremstilling av imidazo-(1,2-C)(2,3)- benzodiazepiner, samt mellomprodukter ved fremstillingen derav
DK1070082T3 (da) Fremgangsmåde til fremstilling af 4,4-dimethyl-5alfa-cholesta-8,14,24-trien-3beta-ol og mellemprodukter i fremgangsmåden (I)
ATE245138T1 (de) Verfahren zur herstellung von 2- trifluormethoxynalin